Core Viewpoint - Peter Schiff has criticized Strategy's heavy investment in Bitcoin, questioning its potential inclusion in the S&P 500 due to a significant decline in performance [1][2] Company Performance - Strategy's stock experienced a 47.5% decline in 2025, which would categorize it among the worst performers if it were part of the S&P 500 [1] - The company's aggressive Bitcoin accumulation has negatively impacted shareholders, undermining the argument that Bitcoin investment is the optimal corporate strategy [2] Market Context - The S&P 500 index saw an overall increase of approximately 17.3% in 2025, following gains of 23.3% in 2024 and 24.2% in 2023, indicating a strong year for the broader U.S. equity market [3] - Despite the overall positive performance of the S&P 500, several large-cap stocks faced significant losses due to specific company challenges and changing market conditions [3] Notable Stock Performances - Fiserv was the worst-performing stock in the S&P 500 in 2025, down roughly 70% after missing earnings expectations and facing client complaints [4] - The Trade Desk followed closely with a decline of around 68%, impacted by slower revenue growth and increased competition [4] - Sarepta Therapeutics experienced a decline of over 80% due to patient deaths and regulatory issues related to its gene therapy treatments [4] - Other notable laggards included Deckers Outdoor, Gartner, and Lululemon Athletica, each losing more than 50% amid weaker forecasts and restructuring efforts [5] Strategy's Stock Movement - Strategy, trading under the ticker MSTR, is not part of the S&P 500 but had a volatile performance in 2025, starting near $300 and gaining about 50% in the first quarter as Bitcoin prices rose [6] - The stock reached an annual high of $457.22 on July 16, 2025, but reversed sharply in the second half of the year as Bitcoin prices fell [6] - By December 31, 2025, MSTR hit an annual low of $151.42, closing the year down approximately 49.35%, making it the worst performer in the Nasdaq-100 [7]

Core Insights - The U.S. Department of Health and Human Services (HHS) has added Duchenne muscular dystrophy (DMD) to the recommended newborn screening panel, which is seen as a significant advancement in early diagnosis and potential treatment opportunities in the biotech sector [1] Group 1: Industry Impact - The addition of DMD to the newborn screening panel is expected to create new market opportunities for biotechnology companies focused on developing therapies for this condition [1] - This decision may lead to increased investment and research in the field of genetic disorders, particularly in the development of innovative treatments for DMD [1] Group 2: Analyst Perspective - The analyst emphasizes the importance of combining scientific expertise with financial analysis to identify promising biotechnology companies that are innovating in unique ways [1] - The focus is on evaluating the science behind drug candidates, the competitive landscape, clinical trial design, and potential market opportunities, while also considering financial fundamentals and valuation [1]

Core Insights - Sarepta Therapeutics reported a third-quarter 2025 adjusted loss of $0.13 per share, missing the Zacks Consensus Estimate of $0.01 EPS, compared to an adjusted EPS of $0.43 in the same period last year [3][4] - Total revenues for the quarter were $399.4 million, down nearly 15% year over year, primarily due to lower sales of Elevidys, but still beating the Zacks Consensus Estimate of $352.6 million [4][5] - The company generated $131.5 million from Elevidys sales, a 27% decline year over year, attributed to the suspension of shipments to non-ambulatory patients amid safety concerns, yet this figure exceeded both the Zacks Consensus Estimate of $107 million and model estimates of $120 million [6][4] Financial Performance - Product revenues fell 14% year over year to $370.0 million, with $238.5 million generated from three PMO therapies, down 4% year over year, but beating estimates [5][4] - Collaboration and other revenues associated with Elevidys supply to Roche were approximately $29.3 million, down nearly 22% year over year due to reduced shipment volumes [7] - Adjusted R&D expenses totaled $206.5 million, up 3% year over year, while adjusted SG&A expenses declined 23% to $77.1 million due to a restructuring plan [8] Guidance and Outlook - Sarepta expects at least $500 million in annual revenue from Elevidys infusions in the ambulant population for 2025, with fourth-quarter infusion volumes anticipated to be flat to slightly down [9] - The company projects combined adjusted SG&A and R&D expenses of $420-$430 million for the full year, including a $200 million milestone payment to Arrowhead Pharmaceuticals [10] - Recent estimates have trended downward, with a consensus estimate shift of -10.82% over the past month, indicating a downward shift in expectations [12][14] Industry Context - Sarepta Therapeutics is part of the Zacks Medical - Biomedical and Genetics industry, where Bristol Myers Squibb reported revenues of $12.22 billion for the last quarter, reflecting a year-over-year change of +2.8% [15] - Bristol Myers is expected to post earnings of $1.65 per share for the current quarter, representing a year-over-year change of -1.2% [16]

Core Insights - Sarepta Therapeutics' shares increased by 7% following the announcement of progress in its phase I/II study for SRP-1003, a therapeutic for type 1 myotonic dystrophy (DM1) [1][8] Study Progress - The company has completed two cohorts of the study and has enrolled patients in a third cohort, with a positive review from a drug safety committee allowing for the advancement of additional dosing cohorts [2] - Currently, patients are being dosed in a fourth cohort, with plans to start the fifth cohort in Q1 2026, and initial readout from the study is expected early next year [2] Stock Performance - Following the announcement, investor sentiment improved, especially in light of safety concerns surrounding other investigational DM1 therapies from competitors [3] - The stock has faced significant challenges this year, dropping nearly 85% compared to the industry’s 17% growth [6] Milestone Payments - The progress in the study triggered a $200 million milestone payment to Arrowhead Pharmaceuticals, part of a multi-billion-dollar licensing deal for SRP-1003 [7][8] - This is the second milestone payment in 2023, with the first being $100 million in July for reaching enrollment targets [9] Additional Acquisitions - Besides SRP-1003, Sarepta has acquired exclusive rights to three other clinical-stage programs from Arrowhead, which are in separate phase I/II studies [10] - Initial data for the facioscapulohumeral muscular dystrophy (FSHD) program is anticipated in early 2026 [10]

Core Insights - The U.S. FDA has approved dosing in Sarepta Therapeutics Inc.'s Cohort 8 of the ENDEAVOR study, which focuses on treating non-ambulant individuals with Duchenne muscular dystrophy using Elevidys [1][2] - Cohort 8 aims to evaluate an enhanced immunosuppressive regimen with sirolimus to reduce acute liver injury associated with Elevidys treatment [2][4] - The study has reported fatalities linked to acute liver failure in patients receiving Elevidys, raising concerns among investors [3] Study Details - Cohort 8 will enroll approximately 25 non-ambulant participants in the U.S. and will include a 14-day sirolimus dosing period before Elevidys administration, followed by 12 weeks of continued dosing [3][4] - Primary endpoints of the study include the incidence of acute liver injury and Elevidys-dystrophin expression at 12 weeks [4] - The ENDEAVOR study has enrolled a total of 55 participants across seven cohorts, assessing various age groups and ambulatory statuses [5] Additional Developments - Sarepta is also progressing in the Phase 1/2 clinical study of SRP-1003 for type 1 myotonic dystrophy, with ongoing dosing in cohort 4 and plans for cohort 5 in early 2026 [6][7] - The completion of earlier cohorts has triggered a $200 million payment to Arrowhead Pharmaceuticals [6]

Core Insights - Sarepta Therapeutics is advancing its investigational siRNA treatment SRP-1003 for Myotonic Dystrophy Type 1, with positive progress reported in the Phase 1/2 clinical study [1][2] Study Progress - Cohorts 1 (1.5 mg/kg) and 2 (3 mg/kg) of the study are complete, while cohort 3 (4.5 mg/kg) is fully enrolled and ongoing [2] - Patients are currently being dosed in cohort 4 (6 mg/kg), with plans to initiate dosing in cohort 5 (12 mg/kg) in early 2026 [3] Financial Milestones - Following a positive review by the drug safety committee, a second milestone payment of USD 200 million will be made to Arrowhead Pharmaceuticals within 60 days [2] siRNA Platform Overview - Sarepta's siRNA platform focuses on therapies for neurodegenerative and pulmonary diseases, with ongoing preclinical programs for Spinocerebellar ataxia types 1 and 3 [3] Company Mission - Sarepta is dedicated to engineering precision genetic medicine for rare diseases, holding leadership positions in Duchenne muscular dystrophy and expanding its portfolio across various disease areas [4]

Core Insights - The FDA has approved significant changes to the label of Sarepta Therapeutics' Elevidys, a gene therapy for Duchenne muscular dystrophy (DMD), narrowing the eligible patient population and adding new safety restrictions [1][2][4]. Summary by Sections Label Changes - Elevidys is now approved only for ambulatory patients aged four years and older with DMD, excluding non-ambulatory patients [2][4]. - A boxed warning has been mandated, highlighting risks of acute liver failure (ALF) and acute liver injury (ALI) [2][4]. - Additional limitations include restrictions for patients with pre-existing liver impairment, recent vaccinations, or active/recent infections [3][8]. Monitoring and Studies - New monitoring requirements include weekly liver function tests for at least three months post-treatment [3][8]. - Patients must remain near a medical facility for at least two months after infusion to ensure rapid access to care if complications arise [3][8]. - Sarepta is required to conduct an observational study enrolling approximately 200 DMD patients to evaluate the risk of serious liver injury over at least 12 months [5][8]. Market Reaction - Despite the substantial label changes, Sarepta's stock rose nearly 6% following the announcement, indicating investor relief that Elevidys was not completely withdrawn from the market [6][8]. - Year-to-date, the stock has plummeted nearly 85%, contrasting with the industry's 15% growth [7]. Future Developments - To address safety issues, Sarepta is developing a revised treatment protocol with an enhanced sirolimus-based immunosuppressive regimen aimed at reducing acute liver complications [10]. - A clinical study of this updated regimen is planned to potentially resume dosing in the non-ambulatory population pending FDA review [10][11].

Core Viewpoint - Sarepta Therapeutics, Inc. experienced a stock price increase following the FDA's issuance of a new boxed warning for its gene therapy Elevidys, which is now restricted to specific patient groups due to safety concerns [1][2]. Summary by Sections FDA Warning and Approval Changes - The FDA added a Boxed Warning to Elevidys, indicating a high level of safety concern due to reports of fatal liver injuries in non-ambulatory pediatric patients [1][5]. - Elevidys is now approved only for ambulatory patients aged four or older with a confirmed Duchenne muscular dystrophy (DMD) gene mutation [2][5]. Safety Concerns and Patient Cases - Reports indicated that affected children experienced severely increased liver enzymes and required hospitalization within two months of treatment [3]. - A serious non-fatal liver injury case involved complications such as mesenteric vein thrombosis, bowel damage, tissue death, and portal hypertension [3]. Stock Performance - Sarepta's stock has declined nearly 50% over the past six months, but it rose by 5.56% to close at $18.81 following the FDA announcement [3].

Core Points - Sarepta Therapeutics, Inc. announced an update to the prescribing information for ELEVIDYS, the only approved gene therapy for Duchenne muscular dystrophy (DMD) [1] - The updated label now includes a boxed warning for the risk of acute serious liver injury (ALI) and acute liver failure (ALF) [1]

Core Insights - The U.S. Food and Drug Administration has approved new labeling for Sarepta Therapeutics' gene therapy Elevidys, which now includes the most serious safety warning [1] - The use of Elevidys is restricted to walking patients diagnosed with Duchenne muscular dystrophy [1] Company Summary - Sarepta Therapeutics' gene therapy Elevidys has received updated labeling from the FDA [1] - The new labeling emphasizes significant safety concerns associated with the treatment [1] Industry Summary - The approval of new labeling by the FDA reflects ongoing regulatory scrutiny in the gene therapy sector [1] - The restriction of Elevidys usage to a specific patient group indicates a trend towards more cautious application of gene therapies in clinical settings [1]